Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPN10200 dose-escalation and dose-finding in adult upper limb spasticity
jRCT2031250290Phase 2Active, not recruiting
- Sponsor
- Ipsen
- Start
- Dec 2025
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of corabotase in Muscle spasm (4 arms), sponsored by Ipsen. Primary endpoints: Safety: treatment-emergent adverse events, Safety: adverse events of special interest and 5 more. Started Dec 2025; status: active, not recruiting.
02
Drugs
corabotase
03
Conditions
Muscle spasm
Beyond the preview
Go deeper on jRCT2031250290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250290.